Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yindan Xintai Pills (银丹心泰丸) is a traditional Chinese medicine (TCM) product developed and marketed by Shenqi Pharmaceutical. It is primarily indicated for the treatment of cardiovascular conditions, including coronary heart disease, stable angina pectoris, and hyperlipidemia. The formulation typically consists of several herbal components, including *Ginkgo biloba* leaf, *Salvia miltiorrhiza* (Danshen), *Gynostemma pentaphyllum*, *Blumea balsamifera* oil, and Borneol. Its therapeutic mechanism is based on TCM principles of promoting blood circulation, resolving blood stasis, and regulating Qi to alleviate symptoms such as chest pain, palpitations, and shortness of breath. The drug is available in oral pill and dripping pill formulations and is listed as an approved pharmaceutical product in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yindan Xintai Pills.